HP
HealthInvest Partners Portfolio holdings
AUM
$234M
1-Year Return
10.88%
This Quarter Return
+15.31%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$51.8M
AUM Growth
+$4.44M
(+9.4%)
Cap. Flow
-$393K
Cap. Flow
% of AUM
-0.76%
Top 10 Holdings %
Top 10 Hldgs %
97.02%
Holding
55
New
45
Increased
2
Reduced
5
Closed
2
Top Buys
| 1 |
GSK
GSK
|
+$5.27M |
| 2 |
CVS Health
CVS
|
+$4.85M |
| 3 |
Cardinal Health
CAH
|
+$2.31M |
| 4 |
Utah Medical Products
UTMD
|
+$804K |
| 5 |
UnitedHealth
UNH
|
+$201K |
Top Sells
| 1 |
McKesson
MCK
|
+$4.42M |
| 2 |
Gilead Sciences
GILD
|
+$3.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$2.37M |
| 4 |
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
|
+$2.26M |
| 5 |
Zevra Therapeutics
ZVRA
|
+$1.93M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Utah Medical Products
UTMD
$200M
| $9.45M | 18.25% |
94,000
+8,000
| +9% | +$804K |
|
|
2
Cardinal Health
CAH
$36.4B
| $7.69M | 14.84% |
100,000
+30,000
| +43% | +$2.31M |
|
3
Cigna
CI
$80.8B
| $5.3M | 10.24% |
16,000
-1,000
| -6% | -$331K |
|
4
Viatris
VTRS
$11.6B
| $5.29M | 10.21% |
475,000
-5,000
| -1% | -$55.7K |
|
|
5
GSK
GSK
$82.2B
| $5.27M | 10.18% |
+150,000
| New | +$5.27M |
|
|
6
Gilead Sciences
GILD
$142B
| $5.22M | 10.07% |
60,760
-44,240
| -42% | -$3.8M |
|
|
7
CVS Health
CVS
$95.1B
| $4.85M | 9.36% |
+52,000
| New | +$4.85M |
|
|
8
Bristol-Myers Squibb
BMY
$94B
| $4.68M | 9.03% |
65,000
-33,000
| -34% | -$2.37M |
|
|
9
Zevra Therapeutics
ZVRA
$435M
| $1.51M | 2.92% |
330,000
-420,000
| -56% | -$1.93M |
|
10
Aurinia Pharmaceuticals
AUPH
$1.68B
| $994K | 1.92% |
230,000
| – | – |
|
|
11
UnitedHealth
UNH
$319B
| $201K | 0.39% |
+379
| New | +$201K |
|
12
AbbVie
ABBV
$386B
| $131K | 0.25% |
+811
| New | +$131K |
|
13
Merck
MRK
$207B
| $123K | 0.24% |
+1,110
| New | +$123K |
|
14
Eli Lilly
LLY
$677B
| $123K | 0.24% |
+335
| New | +$123K |
|
15
Thermo Fisher Scientific
TMO
$181B
| $121K | 0.23% |
+220
| New | +$121K |
|
16
Regeneron Pharmaceuticals
REGN
$59.4B
| $67.1K | 0.13% |
+93
| New | +$67.1K |
|
17
Pfizer
PFE
$136B
| $62.5K | 0.12% |
+1,220
| New | +$62.5K |
|
18
Vertex Pharmaceuticals
VRTX
$101B
| $62.4K | 0.12% |
+216
| New | +$62.4K |
|
19
Cencora
COR
$58.7B
| $51.2K | 0.1% |
+309
| New | +$51.2K |
|
20
Boston Scientific
BSX
$152B
| $49.1K | 0.09% |
+1,061
| New | +$49.1K |
|
21
Stryker
SYK
$147B
| $48.4K | 0.09% |
+198
| New | +$48.4K |
|
22
IQVIA
IQV
$31.8B
| $44.1K | 0.09% |
+215
| New | +$44.1K |
|
23
BioMarin Pharmaceuticals
BMRN
$10.4B
| $42.8K | 0.08% |
+414
| New | +$42.8K |
|
24
DexCom
DXCM
$29.9B
| $33.9K | 0.07% |
+299
| New | +$33.9K |
|
25
Moderna
MRNA
$9.15B
| $33.6K | 0.06% |
+187
| New | +$33.6K |
|